NeoVax

**NeoVax** is an investigational, patient-specific therapeutic cancer vaccine developed at Dana-Farber Cancer Institute. Each individualized vaccine contains up to 20 synthetic long peptides encoding neoantigens selected from mutations identified by sequencing an individual patient's tumor, formulated with the immune adjuvant poly-ICLC. It is designed to prime and expand neoantigen-specific CD4-positive and CD8-positive T-cell responses, thereby directing immune recognition toward tumor cells while sparing normal tissues that lack the selected mutations. NeoVax has been evaluated in early-stage clinical studies across melanoma, glioblastoma, clear cell renal cell carcinoma, ovarian cancer, and chronic lymphocytic leukemia, including combinations with immune checkpoint inhibitors and other immunomodulatory agents.

Brand names

NEO-PV-01NEO-PV01NEO-PV 01

Other names

Personalized NeoAntigen Cancer Vaccinepersonalized neoantigen peptide vaccinepersonalized neoantigen vaccine